americanpharmaceuticalreviewMarch 09, 2020
Tag: Royalty Pharma , Entyvio , IBD
Royalty Pharma has acquired Massachusetts General Hospital's (MGH) royalty interest in Entyvio (vedolizumab) for $94 million. Entyvio is a monoclonal antibody that is used in the treatment of ulcerative colitis and Crohn's disease, two of the most common forms of inflammatory bowel disease (IBD), and is marketed by Takeda Pharmaceutical Company Limited. Entyvio was approved by the U.S. Food & Drug Administration (FDA) in 2014 and is available in more than 60 countries worldwide. In 2019, calendar year sales were in excess of $3 billion and grew over 30% versus 2018.
"Because of the discoveries of researchers at Massachusetts General Hospital, Entyvio has improved the lives of hundreds of thousands of patients with IBD," said Pablo Legorreta, Founder and CEO of Royalty Pharma. "Through transactions such as this, we are furthering our goal of accelerating innovation and making the life sciences research and development ecosystem more efficient and productive."
"The work and dedication of the MGH inventor team of Harvard-appointed pathologists led by Robert Colvin, MD, along with Atul Bhan, MD, James Kurnick, MD, Andrew Lazarovitz, MD, PhD, and Richard Moscicki, MD, is reflective of a system-wide commitment to improving care for patients dealing with challenging conditions," said Chris Coburn, Chief Innovation Officer, Partners HealthCare. "Through this transaction with Royalty Pharma, we'll be able to accelerate our investment in discovery and science for the benefit of patients worldwide. Our congratulations to the remarkable team of pathologists who realized this vision for improving patient care."
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: